Volume 21, Issue 3 (Fall 2010)                   Stud Med Sci 2010, 21(3): 278-285 | Back to browse issues page

XML Persian Abstract Print

, hamidnoshad1@yahoo.com
Abstract:   (17363 Views)

  Received: 19 Feb, 2010 Accepted: 26 May, 2010


  Background & Aims : According to the clinical guidelines on chronic kidney disease with hypertension, combination therapy with multiple renin–angiotensin–aldosterone system (RAAS) blockers have been recommended as standard first-line therapy. To date, dual and triple blockade of the RAAS has been evaluated. The aim of this study was comparing three (ACEI+ARB+ ß blocker) and two (ACEI+ARB) directional inhibitions of RAAS in treatment of diabetic nephropathy.

  Materials & Methods : In an experimental interventional study, 103 diabetic patients without ESRD were recruited in Tabriz Sina Hospital during a one-year period. The patients were randomized in two groups: group A received triple blockade of RAAS with ACEI+ARB+ß blocker, and group B received dual blockade with ACEI+ARB (and placebo). Basal and post treatment parameters including blood pressure, urine albumin, serum BUN, Cr, Na, K , HbA1C, and GFR were compared.

  Results : Both study groups were matched for age, sex and duration of diabetes mellitus. Decrease of blood pressure, albuminuria, BUN, and Cr was more significant in group A compared with group B. The GFR rose more significantly in group A compared with group B. The frequency of hyperkalemia was significantly higher in group A.

  Conclusion : Triple blockade of RAAS is more efficient that dual blockade in prevention of diabetic nephropathy however, meticulous selection of patients should be considered because of higher risk of hyperkalemia.


  Address : Nephrology Department, Tabriz University of Medical Sciences, Tabriz, Iran

  Tel : (+98)9143115927


  Email : hamidnoshad1@yahoo.com


  Source: Urmia Med J 2010: 21(3): 278 ISSN: 1027-3727

Full-Text [PDF 201 kb]   (2276 Downloads)    
Type of Study: Research | Subject: آناتومی

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.